Details for Patent: 9,125,908
✉ Email this page to a colleague
Which drugs does patent 9,125,908 protect, and when does it expire?
Patent 9,125,908 protects TRINTELLIX and is included in one NDA.
Protection for TRINTELLIX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has ninety-three patent family members in thirty-four countries.
Summary for Patent: 9,125,908
| Title: | 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment |
| Abstract: | 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT3 and 5-HT1A and may as such be useful for the treatment of cognitive impairment, especially in depressed patients. |
| Inventor(s): | Benny Bang-Andersen, Arne Mork, Tine Bryan Stensbol, Andre Faldt, Rene Holm, Heidi Lopez De Diego |
| Assignee: | H Lundbeck AS |
| Application Number: | US14/242,510 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,125,908 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,125,908
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-001 | Sep 30, 2013 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-002 | Sep 30, 2013 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-003 | Sep 30, 2013 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| Takeda Pharms Usa | TRINTELLIX | vortioxetine hydrobromide | TABLET;ORAL | 204447-004 | Sep 30, 2013 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,125,908
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Denmark | 2006 00824 | Jun 16, 2006 |
| Denmark | 2006 01223 | Sep 22, 2006 |
| Denmark | 2006 01384 | Oct 25, 2006 |
| Denmark | 2007 00427 | Mar 20, 2007 |
International Family Members for US Patent 9,125,908
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 061481 | ⤷ Start Trial | |||
| Argentina | 065797 | ⤷ Start Trial | |||
| Austria | E495745 | ⤷ Start Trial | |||
| Austria | E540941 | ⤷ Start Trial | |||
| Australia | 2007260355 | ⤷ Start Trial | |||
| Australia | 2008228638 | ⤷ Start Trial | |||
| Brazil | 122020011899 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
